Skip to main content

Table 1 Baseline characteristics of patients with axial spondyloarthritis from the PROOF and GESPIC cohorts

From: Deep learning for detection of radiographic sacroiliitis: achieving expert-level performance

Parameter at baseline PROOF (n = 1553) GESPIC (n = 458)
Age, years, mean (SD) 34.7 (10.5) 35.7 (10.3)
Male sex, n (%) 983 (63.3) 243 (53.1)
Duration of symptoms, years, mean (SD) 4.7 (6.8) 4.0 (2.7)
HLA-B27 positive, n (%) 836 (64.6) 359 (78.4)
CRP, mg/l, mean (SD) 15.6 (23.0) 11.5 (18.2)
ASDAS-CRP, mean (SD) 2.9 (1.1) 2.6 (1.0)
BASDAI, 0–10, mean (SD) 4.5 (2.3) 3.9 (2.1)
BASFI, 0–10, mean (SD) 3.3 (2.5) 2.8 (2.3)
Peripheral arthritis, n (%) 503 (32.4) 65 (14.2)
Uveitis, n (%) 151 (9.7) 79 (17.3)
Psoriasis, n (%) 106 (6.8) 49 (10.7)
IBD, n (%) 40 (2.6) 12 (2.6)
Family history of SpA, n (%) 291 (18.7) 147 (32.1)
Treatment with NSAIDs, n (%) 1204 (77.5) 305 (66.6)
Treatment with csDMARDs, n (%) 539 (34.7) 107 (23.4)
Treatment with systemic steroids, n (%) 119 (7.7) 40 (8.7)
Treatment with a TNF inhibitor, n (%) 234 (15.1) 11 (2.4)
  1. ASDAS-CRP C-reactive protein-based ankylosing spondylitis disease activity score, axSpA axial spondyloarthritis, BASDAI Bath Ankylosing Spondylitis Disease Activity Index, BASFI Bath Ankylosing Spondylitis Functional Index, CRP C-reactive protein, csDMARDs conventional synthetic disease-modifying antirheumatic drugs, IBD inflammatory bowel disease, nr-axSpA non-radiographic axial SpA, NSAIDs non-steroidal anti-inflammatory drugs, r-axSpA radiographic axial SpA, SD standard deviation, SpA spondyloarthritis, TNF tumour necrosis factor